Eversept Partners LP Grows Position in Geron Corporation $GERN

Eversept Partners LP increased its position in shares of Geron Corporation (NASDAQ:GERN) by 40.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,659,983 shares of the biopharmaceutical company’s stock after buying an additional 5,060,981 shares during the period. Geron comprises about 1.2% of Eversept Partners LP’s portfolio, making the stock its 19th biggest position. Eversept Partners LP owned 2.77% of Geron worth $23,311,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. 55 North Private Wealth LLC purchased a new stake in shares of Geron during the fourth quarter worth approximately $29,000. LCM Capital Management Inc increased its stake in shares of Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 10,000 shares during the period. Vistica Wealth Advisors LLC purchased a new stake in shares of Geron during the fourth quarter worth approximately $33,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 24,410 shares during the period. Finally, Swiss Life Asset Management Ltd increased its stake in shares of Geron by 73.6% during the third quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 11,182 shares during the period. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Price Performance

Shares of NASDAQ:GERN opened at $1.23 on Thursday. The company’s fifty day moving average price is $1.40 and its 200 day moving average price is $1.44. Geron Corporation has a 12 month low of $1.04 and a 12 month high of $2.01. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96. The firm has a market capitalization of $789.07 million, a P/E ratio of -11.18 and a beta of 0.60.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. Geron had a negative net margin of 35.48% and a negative return on equity of 23.31%. The firm had revenue of $51.84 million for the quarter, compared to analyst estimates of $50.59 million. As a group, sell-side analysts predict that Geron Corporation will post -0.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 26th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $2.50.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.